Insulet Ownership
| PODD Stock | USD 269.99 3.31 1.24% |
Shares in Circulation | First Issued 2005-03-31 | Previous Quarter 74 M | Current Value 74.1 M | Avarage Shares Outstanding 48.2 M | Quarterly Volatility 21.9 M |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
Insulet |
Insulet Stock Ownership Analysis
About 99.0% of the company shares are owned by institutional investors. The company recorded earning per share (EPS) of 5.78. Insulet had not issued any dividends in recent years. Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts. Insulet Corp operates under Medical Devices classification in the United States and is traded on NASDAQ Exchange. It employs 2300 people. To find out more about Insulet contact James Hollingshead at 978 600 7000 or learn more at https://www.insulet.com.Besides selling stocks to institutional investors, Insulet also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Insulet's stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Insulet's strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Insulet Quarterly Liabilities And Stockholders Equity |
|
Insulet Insider Trades History
Less than 1% of Insulet are currently held by insiders. Unlike Insulet's institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Insulet's private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Insulet's insider trades
Insulet Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Insulet is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Insulet backward and forwards among themselves. Insulet's institutional investor refers to the entity that pools money to purchase Insulet's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Amvescap Plc. | 1.2 M | Jpmorgan Chase & Co | 2024-09-30 | 1.1 M | Groupama Asset Management | 2024-12-31 | 1.1 M | Citadel Advisors Llc | 2024-09-30 | 990.5 K | Norges Bank | 2024-12-31 | 953 K | American Century Companies Inc | 2024-12-31 | 854.9 K | Artisan Partners Limited Partnership | 2024-12-31 | 770.2 K | Northern Trust Corp | 2024-12-31 | 738.8 K | Macquarie Group Ltd | 2024-12-31 | 691 K | Vanguard Group Inc | 2024-12-31 | 8.5 M | Fmr Inc | 2024-12-31 | 7.8 M |
Insulet Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Insulet insiders, such as employees or executives, is commonly permitted as long as it does not rely on Insulet's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Insulet insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Insulet's latest congressional trading
Congressional trading in companies like Insulet, is subject to rigorous scrutiny to prevent conflicts of interest and insider trading. This is governed by multiple SEC regulations which were established to foster transparency and deter members of Congress from leveraging non-public information for personal gain. This oversight helps maintain public trust and ensures that investments in Insulet by those in governmental positions are based on the same information available to the general public.
| 2024-04-19 | Senator Tina Smith | Acquired $50K to $100K | Verify | ||
| 2024-04-18 | Senator Tina Smith | Acquired $50K to $100K | Verify | ||
| 2024-01-26 | Senator Markwayne Mullin | Acquired Under $15K | Verify | ||
| 2024-01-25 | Senator Markwayne Mullin | Acquired Under $15K | Verify | ||
| 2018-09-19 | Senator Tina Smith | Acquired $250K to $500K | Verify | ||
| 2018-09-18 | Senator Tina Smith | Acquired $15K to $50K | Verify | ||
| 2018-06-11 | Senator Tina Smith | Acquired $100K to $250K | Verify | ||
| 2018-06-10 | Senator Tina Smith | Acquired $100K to $250K | Verify | ||
| 2018-03-06 | Senator Tina Smith | Acquired $100K to $250K | Verify | ||
| 2018-03-05 | Senator Tina Smith | Acquired $100K to $250K | Verify |
Insulet Outstanding Bonds
Insulet issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Insulet uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Insulet bonds can be classified according to their maturity, which is the date when Insulet has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| US45782BAD64 Corp BondUS45782BAD64 | View | |
| Installed Building Products Corp BondUS45780RAA95 | View | |
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| MGM Resorts International Corp BondUS552953CD18 | View |
Insulet Corporate Filings
10K | 21st of February 2025 Annual report required by the U.S. Securities and Exchange Commission (SEC) of a company financial performance | ViewVerify |
8K | 20th of February 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
F4 | 19th of February 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
13A | 12th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Insulet is a strong investment it is important to analyze Insulet's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Insulet's future performance. For an informed investment choice regarding Insulet Stock, refer to the following important reports:Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Insulet. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment. For information on how to trade Insulet Stock refer to our How to Trade Insulet Stock guide.You can also try the Price Transformation module to use Price Transformation models to analyze the depth of different equity instruments across global markets.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Insulet. If investors know Insulet will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Insulet listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.06) | Earnings Share 5.78 | Revenue Per Share | Quarterly Revenue Growth 0.172 | Return On Assets |
The market value of Insulet is measured differently than its book value, which is the value of Insulet that is recorded on the company's balance sheet. Investors also form their own opinion of Insulet's value that differs from its market value or its book value, called intrinsic value, which is Insulet's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Insulet's market value can be influenced by many factors that don't directly affect Insulet's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Insulet's value and its price as these two are different measures arrived at by different means. Investors typically determine if Insulet is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Insulet's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.